Figure 2. Evaluation of ⁶⁸Ga-HZ20 in the rhACE2-subcutaneous models. (A) PET imaging with⁶⁸Ga-HZ20 in the KM mice model with subcutaneous injection of different doses of rhACE2. The white circle indicates the injection site of rhACE2. (K, B stands for kidney and bladder). (B) PET imaging of mice treated with 0.4 nmol rhACE2 and without or with 50 μg HZ20 blocking. The white box indicates the injection site of rhACE2. (K, B stands for kidney and bladder). (C) Comparison of SUVmax at the rhACE2 injection site in Figure 2A and Figure S4. (D) The ratio of shoulder to muscle SUVmax. (E) ex vivo imaging of the injection site and major organs. (F) Correlation analysis between SUVmax and rhACE2 doses at 120 min after injection. (G) Comparison of SUVmax in the 0.4 nmol and 0.4 nmol block groups. (H) Western blot of rhACE2 at the injection site.